Status and phase
Conditions
Treatments
About
In this trial HLA-A2+ patients with WT1 expressing carcinomas are vaccinated with a peptide from the leukemia associated antigen WT1 together with immunological adjuvants KLH as T-helper protein and GM-CSF
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
Loading...
Central trial contact
Carmen Scheibenbogen, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal